S-(+)-2-Butyl-t-butylether | 51067-82-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: S-(+)-2-Butyl-t-butylether
• 英文别名: (S)-2-tert-butoxy-butane；(S)-sec-butyl tert-butyl ether；1,1-Dimethylethyl 1-methylpropyl ether；(2S)-2-[(2-methylpropan-2-yl)oxy]butane
• CAS: 51067-82-4
• 化学式: C₈H₁₈O
• 分子量: 130.23
• InChiKey: WMZNUJPPIPVIOD-ZETCQYMHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  (S)-2-methyl-peroxybutyric acid tert-butyl ester 生成 S-(+)-2-Butyl-t-butylether
  参考文献：
  名称：

  Retention in the combination of optically active 2-butyl-tert-butoxy radical pairs

  摘要：

  DOI：

  10.1021/ja00806a066

文献信息

• Mitotic Kinesin Inhibitors and Methods of Use Thereof
  申请人：Hans Jeremy

  公开号：US20080182992A1

  公开（公告）日：2008-07-31

  This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders.

  本发明涉及有丝分裂动力蛋白酶抑制剂，特别是KSP的抑制剂，以及制备这些抑制剂的方法。该发明还提供了包含该发明抑制剂的药物组合物，并且提供了利用该发明抑制剂和药物组合物在治疗和预防各种疾病中的方法。
• Crf Receptor Antagonists And Methods Relating Thereto
  申请人：Lanier Marion

  公开号：US20080064719A1

  公开（公告）日：2008-03-13

  CRF receptor antagonists are disclosed which may have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in mammals, such as stroke. The CRF receptor antagonists of this invention have the following structure: and pharmaceutically acceptable salts, esters, solvates, stereoisomers and prodrugs thereof, wherein R 1 , R 2 , n, R 5 , Ar, and Het are as defined herein. Compositions containing a CRF receptor antagonists in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.

  本发明公开了CRF受体拮抗剂，可用于治疗多种疾病，包括治疗哺乳动物中CRF分泌过多表现的疾病，如中风。本发明的CRF受体拮抗剂具有以下结构：以及其药学上可接受的盐、酯、溶剂合物、立体异构体和前药，其中R1、R2、n、R5、Ar和Het的定义如本文所述。本发明还公开了含有CRF受体拮抗剂和药学上可接受的载体的组合物，以及使用它们的方法。
• MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF
  申请人：Ahrendt Kateri

  公开号：US20100041719A1

  公开（公告）日：2010-02-18

  This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment of various disorders.

  本发明涉及有丝分裂动力蛋白酶抑制剂，特别是KSP的抑制剂，以及制备这些抑制剂的方法。本发明还提供包括本发明抑制剂的药物组合物，以及利用这些抑制剂和药物组合物治疗各种疾病的方法。
• CHEMICAL SYNTHESIS AND ANTI-TUMOR AND ANTI-METASTATIC EFFECTS OF DUAL FUNCTIONAL CONJUGATE
  申请人：Shenzhen Salubris Pharmaceuticals Co., Ltd.

  公开号：EP2612857B1

  公开（公告）日：2017-07-26
• SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS
  申请人：MAX-PLANCK-GESELLSCHART ZUR FÖRDERUNG DER WISSENSC HAFTEN E.V.

  公开号：US20160289184A1

  公开（公告）日：2016-10-06

  The present invention relates to compounds of the general formula (I) having a selective FKBP51 ligand scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said selective FKBP51 ligand compounds can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions.